First patient dosed in the MIV-818 combination study
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with hepatocellular carcinoma (HCC) has been dosed with MIV-818 in a phase 1b/2a combination study with the company's candidate drug MIV-818. In the study, MIV-818 will be given in combination with two other medicines, either with Lenvima®, a tyrosine kinase inhibitor, or with Keytruda®, an anti-PD-1 checkpoint inhibitor. Lenvima® and Keytruda®, respectively, are currently approved as monotherapy treatments of HCC*. The purpose of the study is to evaluate safety, tolerability and also to get an